Healthcare Global Enterprises Intrinsic Value
Healthcare Global Enterprises (HCG) median intrinsic value is ₹199.96 from 8 valuation models (range ₹133–₹289), vs current price ₹666.55 — -70.0% downside (Trading Above Calculated Value), margin of safety -100.0%. Read Healthcare Global Enterprises dividend payments for the complete payout history and dividend yield track record.
HCG Valuation Methods Summary — DCF, Graham Number & P/E
Healthcare Global Enterprises intrinsic value across 8 models vs current price ₹666.55 — upside/downside and value range per method. Analyse HCG FII DII holdings to track promoter, FII and institutional holdings.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹199.96 | ₹159.97 - ₹239.95 | -70.0% | EPS: ₹0.60, Sector P/E: 12x |
| Book Value Method | asset | ₹133.31 | ₹119.98 - ₹146.64 | -80.0% | Book Value/Share: ₹89.40, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹199.96 | ₹179.96 - ₹219.96 | -70.0% | Revenue/Share: ₹178.26, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹266.62 | ₹239.96 - ₹293.28 | -60.0% | EBITDA: ₹420.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹288.99 | ₹231.19 - ₹346.79 | -56.6% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹199.96 | ₹179.96 - ₹219.96 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹199.96 | ₹179.96 - ₹219.96 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| Graham Defensive Method | conservative | ₹199.96 | ₹179.96 - ₹219.96 | -70.0% | EPS: ₹0.60, BVPS: ₹89.40 |
HCG Intrinsic Value vs Market Price — All Valuation Models
Healthcare Global Enterprises fair value range ₹133–₹289 vs current market price ₹666.55 across 8 valuation models. For current market price and key ratios, visit HCG screener.
HCG Intrinsic Value Analysis — Undervalued or Overvalued?
Healthcare Global Enterprises median intrinsic value ₹199.96, current price ₹666.55 — Trading Above Calculated Value by 70.0%, margin of safety -100.0%.
What is the intrinsic value of HCG?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Healthcare Global Enterprises (HCG) is ₹199.96 (median value). With the current market price of ₹666.55, this represents a -70.0% variance from our estimated fair value.
The valuation range spans from ₹133.31 to ₹288.99, indicating ₹133.31 - ₹288.99.
Is HCG undervalued or overvalued?
Based on our multi-method analysis, Healthcare Global Enterprises (HCG) appears to be trading above calculated value by approximately 70.0%.
HCG Financial Health — Key Ratios vs Industry Benchmarks
Healthcare Global Enterprises financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 0.76 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 1.2% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 14.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.68x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
HCG Cash Flow Quality — Operating & Free Cash Flow
Healthcare Global Enterprises operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹317 Cr | ₹73 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹285 Cr | ₹172 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹252 Cr | ₹186 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹220 Cr | ₹220 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹121 Cr | ₹36 Cr | Positive Free Cash Flow | 7/10 |